News
IGMS
7.78
+15.19%
1.03
Weekly Report: what happened at IGMS last week (0415-0419)?
Weekly Report · 1d ago
Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)
TipRanks · 5d ago
What 5 Analyst Ratings Have To Say About IGM Biosciences
GM Biosciences is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and other diseases. In the last three months, 5 analysts have published ratings on IGM B biosciences. The company has an average price target of $17.2 with a 12-month growth rate of 75.0%. The company is expected to reach $12.00 in 12 months.
Benzinga · 5d ago
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target
Benzinga · 5d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
TipRanks · 5d ago
IGM BIOSCIENCES: UNDER AGREEMENT, WILL BE ELIGIBLE TO RECEIVE UP TO $1,065 MLN IN AGGREGATE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES/TARGET
Reuters · 6d ago
Weekly Report: what happened at IGMS last week (0408-0412)?
Weekly Report · 04/15 09:20
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 04/10 12:10
Weekly Report: what happened at IGMS last week (0401-0405)?
Weekly Report · 04/08 09:21
Weekly Report: what happened at IGMS last week (0325-0329)?
Weekly Report · 04/01 09:21
Igm Biosciences, Inc.: Statement of changes in beneficial ownership of securities
Press release · 03/29 04:02
Weekly Report: what happened at IGMS last week (0318-0322)?
Weekly Report · 03/25 09:21
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)
TipRanks · 03/19 12:50
Weekly Report: what happened at IGMS last week (0311-0315)?
Weekly Report · 03/18 09:21
Igm Biosciences, Inc.: Report of proposed sale of securities
Press release · 03/14 02:01
IGM Biosciences Price Target Raised to $12.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 03/12 10:55
IGM Biosciences Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 03/12 10:55
IGM Biosciences: A Balanced Hold Rating Amid Financial Stability and Drug Development Risks
TipRanks · 03/12 10:27
Weekly Report: what happened at IGMS last week (0304-0308)?
Weekly Report · 03/11 09:21
More
Webull provides a variety of real-time IGMS stock news. You can receive the latest news about Igm Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IGMS
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.